INFECTION MIMETIC TUMOR FEVER IN ALBANIAN ADULTS: EPIDEMIOLOGICAL AND NOSOGRAPHICAL DATA

  • M. Qato Infectious UHC Mother Theresa Disease Service
  • Dh. Kraja Infectious UHC Mother Theresa Disease Service
  • A. Harxhi Infectious UHC Mother Theresa Disease Service
  • N. Como Infectious UHC Mother Theresa Disease Service
  • P. Pipero Infectious UHC Mother Theresa Disease Service
  • I. Akshija Statistical Service, UHC Mother Theresa
Keywords: Fever, Profile, Tumor, Epidemiological, Clinical

Abstract

Introduction: Tumoral pathologies are often presented as acute or prolonged febrile syndromes, with fever as the only dominant clinical pattern.

Material and Methods: 123 patients, during 2010-2015, age groups 20-70 years. This study is based on an epidemiological (gender, age group, and residence) and clinical survey (history, clinical, biological and serological data)

Results: Epidemiological Males were 79 cases and females 44 cases. Mean age was 45 yrs old, resident in town 82, countryside 41. Clinical A. Tumors Head and neck 9 (cerebral 7 ,thyroid 2 ) Thorax 11( pulmonar adenocarcinoma 8, breast 3 ) Digestive tract 49 ( gastric cancer 4, colon 16,pancreas 15, liver 8, billiary tract 6) Lymphohemopoetic system 46 ( leucosis 19 ,lymphoma 17, myeloma 8, Hairy Cell Leukemia 2) Urogenital tract 8 ( renal cancer 2,prostatic 2, seminoma 1,ovarian 3) B Fever profile and corresponding tumor Continuous (cerebral 3, thyroid 2, pulmonar 6 ,colon 6,intestinal 1, pancreas 5, acute leucosis 8 , billiary tract 2, renal 1 ,seminoma1, breast 1) Remmitent (cerebral 2, colon 5, intestinal 2, pancreas 4, liver 2, billiary tract 2, acute leucosis 2, HCL 2, seminoma 1,breast 2) Intermmitent (cerebral 2, pulmonar 2, liver 6, billiary tract 2, pancreas 6 ,colon 5, renal 1) Recurrent (lymphoma 7, acute leucosis 2, myeloma 2) Ondulant (lymfoma 10, acute leucosis 3, myeloma 6 )

Conclusion: We identified 17 types of febrile tumors and 5 different types of fever. Continuous fever dominated with 29.3% of cases. Diagnostic orientation to malignances followed a detailed anamnestic, laboratory and imagery screening.

Downloads

Download data is not yet available.

References

1. Horowitz HW. Fever of unknown origin or fever of too many origins? The New England Journal of Medicine 2013; 368(3):197–199.
2. Vanderschueren S, Knockaert D, Adriaenssens T, et al. From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch Intern Med 2003; 163:1033-41.
3. Bleeker-Rovers CP, Vos FJ, de Kleijn EMHA, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol.
Medicine (Baltimore) 2007; 86:26-38.
4. Toussaint E, Bahel-Ball E, Vekemans M, Georgala A, Al-Hakak L, Paesmans M, Aoun M. Causes of fever in cancer patients (prospective study over 477 episodes). Supportive Care in Cancer 2006; 14(7):763–769.
5. Bodel P. Generalized perturbations in host physiology caused by localized tumors. Tumors and fever. Ann N Y Acad Sci 1974; 230:6–13.
6. Browder AA, Huff JW, Petersdorf RG. The Significance of Fever in Neoplastic Disease. Annals of Internal Medicine 1961; 55(6):932-942.
7. Boggs, DR and Frei E. Clinical studies of fever and infection in cancer. Cancer 1960; 13(6):1240–1253.
8. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001;92(6 Suppl):1684–1688.
9. Beaupre DM, Talpaz M, Marini FC, Cristiano RJ, Roth JA, Estrov Z, et al. Autocrine Interleukin-1? Production in Leukemia Evidence for the Involvement of Mutated RAS6. Cancer Research 1999:59(12):2971–2980.
10. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. Journal of Clinical
Oncology1995;13(3):575–582.
11. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin’s disease. The American Journal of Medicine 1997;102(1):21–28.
12. Fayad L, Keating MJ, Reuben JM, O’Brien S, Lee BN, Lemer S, Kuzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001;97(1):256–263.
13. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Research 1992;52(12):3317–3322.
14. Tran TT, Liu Y, Zurita A, Lin Y, BakerNeblett KL, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncology 2012;13(8):827–837.
15. Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Annals of Internal Medicine 1997;127(3):186–194.
16. Zell JA and Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Supportive Care in Cancer 2005;13(11):870–877
17. Chang JC and Gross HM. Utility of naproxen in the differential diagnosis of fever of undetermined origin in patients with cancer. The American Journal of Medicine 1984;76(4):597–603.
18. Chang JC and Gross HM. Neoplastic fever responds to the treatment of an adequate dose of naproxen. Journal of Clinical Oncology 1985;3(4):552–558.
19. Chang JC. How to differentiate neoplastic fever from infectious fever in patients with cancer: usefulness of the naproxen test. Heart Lung 1987;16:122–127
20. Economos K, Lucci JA, Richardson B, Yazigi R, Miller DS. The effect of naproxen on fever in patients with advanced gynecologic malignancies. Gynecologic Oncology 1995;56(2):250–254.
21. Tsavaris N, Zinelis A, Karabelis A, Beldecos D, Bacojanis C, Milonacis N, et al. A randomized trial of the effect of three non?steroid antiinflammatory agents in ameliorating cancer?induced fever. Journal of Internal Medicine 1990;228(5):451–455
22. Kathula SK, Shah K, Polenakovik H, Koduri J. Cyclo-oxygenase II inhibitors in the treatment of neoplastic fever. Supportive Care in Cancer 2003;11(4):258–259
23. Lusch CJ, Serpick AA, Slater L. Antipyretic effect of indomethacin in patients with malignancy. Cancer 1968;21(4):781–786.
24. Vanderschueren S, Knockaert DC, Peetermans WE, Bobbaers HJ. Lack of value of the naproxen test in the differential diagnosis of prolonged febrile illnesses. The American Journal of Medicine 2003;115(7):572–575
25. Alsirafy SA, Mesidy El SM, Abou-Elela EN, Elfaramawy YI. Naproxen test for neoplastic fever may reduce suffering. Journal of Palliative Medicine 2011;14(5):665–667.
26. Kallio R, Bloigu A, Surcel HM, Syrjala H. C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas. Support Care Cancer 2001;9:124–128.
27. Chang JC. Antipyretic effect of naproxen and corticosteroids on neoplastic fever. Journal of Pain and Symptom Management 1988;3(3):141– 144.
How to Cite
1.
M. Qato, Dh. Kraja, A. Harxhi, N. Como, P. Pipero, I. Akshija. INFECTION MIMETIC TUMOR FEVER IN ALBANIAN ADULTS: EPIDEMIOLOGICAL AND NOSOGRAPHICAL DATA. Med. res. chronicles [Internet]. 2018Jun.30 [cited 2024Apr.26];5(3):260-6. Available from: https://medrech.com/index.php/medrech/article/view/312
Issue
Vol. 5 No. 3 (2018): May-Jun
Section
Original Research Article